Australian company Prota Therapeutics has completed a major capital raise to support a late-stage clinical trial of its investigative therapy for peanut allergy.
Australian company to progress peanut allergy candidate to late-stage trial
January 22, 2024 Latest NewsBioPharmaLatest Video
New Stories
-
Parliamentary inquiry recommends reforming access arrangements for lobbyists
May 8, 2024 - - Latest News -
Island announces reallocation of US grant funding to support dengue fever trial
May 8, 2024 - - Latest News -
New TGA approvals for UCB's interleukin inhibitor
May 8, 2024 - - Latest News -
Home Affairs Minister reveals the facts on the independence of advisory committees
May 8, 2024 - - BioPharma -
AusBiotech policy leader appointed to lead BioMelbourne Network
May 8, 2024 - - BioPharma -
Momentum Clinical Research recruiting for Australian-based clinical trials
May 7, 2024 - - Australian Biotech -
TGA seeks nominations for statutory advisory committees
May 7, 2024 - - Latest News